Effects of drugs and lesions on dopamine-stimulated adenylate cyclase: evidence for different classes of dopamine receptors
Katzman, R.; Makman, M.H.; Ahn, H.S.; Mishra, R.K.; Gardner, E.
Transactions of the American Neurological Association 102: 76-79
1977
ISSN/ISBN: 0065-9479 PMID: 98893 Document Number: 115595
Document emailed within 1 workday
Related Documents
Woodruff, G.N.; Freedman, S.B.; Poat, J.A. 1980: Why does sulpiride not block the effect of dopamine on the dopamine-sensitive adenylate cyclase? Journal of Pharmacy and Pharmacology 32(11): 802-803van Vliet, B.J.; Mulder, A.H.; Schoffelmeer, A.N. 1990: Mu-opioid receptor-mediated inhibition of D-1 dopamine receptor stimulated adenylate cyclase in primary cultures of rat neostriatal neurons Progress in Clinical and Biological Research 328: 409-412
Mei, Y.A. 1999: High-voltage-activated calcium current and its modulation by dopamine D4 and pituitary adenylate cyclase activating polypeptide receptors in cerebellar granule cells Zhongguo Yao Li Xue Bao 20(1): 3-9
Arbuthnott, G.W.; Attree, T.J.; Eccleston, D.; Loose, R.W.; Martin, M.J. 1974: Is adenylate cyclase the dopamine receptor? Medical Biology 52(5): 350-353
Christensen, C.B.; Mørk, A.; Geisler, A. 1991: Morphine-6-glucuronide and morphine: mu-opioid receptor binding and effects on dopamine-sensitive adenylate cyclase in striatum Pharmacology and Toxicology 69(5): 396-398
Collier, W.L.; De Rossi, M.; Amenta, F. 1984: Dopamine-sensitive adenylate-cyclase in rabbit superior mesenteric artery Archives Internationales de Pharmacodynamie et de Therapie 268(1): 106-112
Cornfield, L.J.; Nelson, D.L.; Monroe, P.J.; Taylor, E.W.; Nikam, S.S. 1988: Use of forskolin stimulated adenylate cyclase in rat hippocampus as a screen for compounds that act through 5-HT1A receptors Proceedings of the Western Pharmacology Society 31: 265-267
Northup, J.K.; Mansour, T.E. 1978: Adenylate cyclase from Fasciola hepatica. 1. Ligand specificity of adenylate cyclase-coupled serotonin receptors Molecular Pharmacology 14(5): 804-819
Rupniak, N.M.; Jenner, P.; Marsden, C.D. 1981: The absence of sodium ions does not explain the failure of sulpiride to inhibit, in vitro, rat striatal dopamine-sensitive adenylate cyclase Journal of Pharmacy and Pharmacology 33(9): 602-603
Hoffmann, I.S.; Talmaciu, R.K.; Cubeddu, L.X. 1986: Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release Journal of Pharmacology and Experimental Therapeutics 238(2): 437-446
Zaremba, T.G.; Fishman, P.H. 1984: Desensitization of catecholamine-stimulated adenylate cyclase and down-regulation of beta-adrenergic receptors in rat glioma C6 cells. Role of cyclic AMP and protein synthesis Molecular Pharmacology 26(2): 206-213
Dwoskin, L.P.; Zahniser, N.R. 1986: Robust modulation of [3H]dopamine release from rat striatal slices by D-2 dopamine receptors Journal of Pharmacology and Experimental Therapeutics 239(2): 442-453
Tadori, Y.; Kobayashi, H. 2014: The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors Nihon Shinkei Seishin Yakurigaku Zasshi 34(5-6): 127-132
Kohli, J.D.; Weder, A.B.; Goldberg, L.I.; Ginos, J.Z. 1980: Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors Journal of Pharmacology and Experimental Therapeutics 213(2): 370-374
O'Hara, C.M.; Tang, L.; Taussig, R.; Todd, R.D.; O'Malley, K.L. 1996: Dopamine D2L receptor couples to G alpha i2 and G alpha i3 but not G alpha i1, leading to the inhibition of adenylate cyclase in transfected cell lines Journal of Pharmacology and Experimental Therapeutics 278(1): 354-360
Morelli, A.; Narducci, F.; Camardella, G.; Pelli, M.A.; Floridi, A.; Nenci, G.G. 1977: Dopamine uptake by platelets in hepatic encephalopathy; evidence for a possible depletion of brain dopamine Acta Hepato-Gastroenterologica 24(6): 405-410
Randrup, A.; Mogilnicka, E. 1976: Spectrum of pharmacological actions on brain dopamine. Indications for development of new psychoactive drugs. Discussion of amantadines as examples of new drugs with special actions on dopamine systems Polish Journal of Pharmacology and Pharmacy 28(6): 551-556
Wustmann, C.; Rudolph, E.; Schwipper, U.; Ranacher, B.; Fischer, H.D.; Schmidt, J. 1982: Effect of nootropic drugs on the dopamine release and dopamine uptake in structures of the rat striatum Acta Biologica et Medica Germanica 41(6): 575-579
Rabin, R.A.; Bode, D.C.; Molinoff, P.B. 1985: Differential effects of cytosolic modulators of fluoride-stimulated adenylate cyclase activity in striatum and cerebral cortex Alcohol and Drug Research 6(6): 379-386
Wang, H.Y.; Undie, A.S.; Friedman, E. 1995: Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation Molecular Pharmacology 48(6): 988-994